TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Hepatocellular Carcinoma|Metastatic Castration Resistant Prostate Cancer|Renal Cell Carcinoma|Non-small Cell Lung Cancer|Colorectal Cancer|Squamous Cell Carcinoma of Head and Neck|Triple-Negative Breast Cancer|Urothelial Carcinoma|Cholangiocarcinoma|GastroEsophageal Cancer|Pancreatic Cancer|Sarcoma
Interventions: DRUG: Part 1 TPST-1120|DRUG: Part 2 TPST-1120 + nivolumab|DRUG: Part 3 TPST-1120|DRUG: Part 4 TPST-1120 + nivolumab
Sponsor: Tempest Therapeutics